Capn4 promotes esophageal squamous cell carcinoma metastasis by regulating ZEB1 through the Wnt/β-catenin signaling pathway

Yun-Long Zhao, Jing-Bo Li, Ying-Jie Li, Shao-Jun Li, Shao-Hua Zhou & Hui Xia

Department of Cardiothoracic Surgery, First Affiliated Hospital of Chinese PLA General Hospital, Beijing, China

Keywords
Capn4; esophageal squamous cell carcinoma (ESCC); metastasis; ZEB1.

Abstract
Background: Capn4 and ZEB1 play important roles in the metastasis of several types of cancer. However, the roles and relationship of Capn4 and ZEB1 in esophageal squamous cell carcinoma (ESCC) remain unclear.

Methods: ESCC tumor tissues and corresponding normal esophageal epithelial tissues were obtained from 86 patients undergoing resection surgery at the Department of General Surgery, First Affiliated Hospital of Chinese PLA General Hospital from 2012 to 2017. Cell migration and invasion were examined via quantitative real-time PCR and Western blot assay.

Results: Our results indicate that both Capn4 and ZEB1 are significantly upregulated in ESCC tissues compared to corresponding adjacent tissues, and a positive correlation between expression and associated malignant characteristics was found. Silencing of Capn4 expression markedly inhibited ESCC invasion and metastasis in vitro and in vivo, and was accompanied by decreased ZEB1 expression. Furthermore, the anti-metastasis role of Capn4 silencing was reversed by ZEB1 overexpression, whereas knockdown of ZEB1 decreased ESCC metastasis driven by the upregulation of Capn4. Mechanistically, Capn4 regulated ZEB1 expression via activation of the Wnt/β-catenin signaling pathway in ESCC cells.

Conclusion: Overall, our results show that enhanced Capn4 expression activates the Wnt/β-catenin signaling pathway, resulting in increased ZEB1 expression and the promotion of ESCC cell metastasis.

Introduction
Esophageal squamous cell carcinoma (ESCC) is one of the most aggressive carcinomas of the gastrointestinal tract worldwide. Despite improvements in detection and therapy, the five-year survival of this malignancy remains below 20%. High invasive potential and distant metastasis are considered major obstacles to satisfactory treatment outcomes. Therefore, a better understanding of the molecular mechanisms of invasion and metastasis of ESCC may be helpful for developing new treatment strategies for this deadly disease.

Capn4, also known as CAPNS1, acts as a binding partner to form a heterodimer with the 80 kDa large catalytic subunit and plays an essential role in maintaining calpain activity. Recent studies have shown that Capn4 expression is associated with oncogenesis in solid tumors, such as ovarian, breast, and colorectal cancers. Emerging evidence has linked the biologic function of Capn4 to tumor metastasis. For instance, Capn4 silencing results in markedly decreased migration and invasion of nasopharyngeal carcinoma cells. Dai et al. found that Capn4 promotes hepatocellular carcinoma metastasis by activating the focal adhesion kinase-steroid receptor coactivator signaling pathway. However, the role of Capn4 expression and its specific mechanism of action in the process of ESCC metastasis are still unclear.

Metastasis of epithelium-derived cancers, including ESCC, is a multistep process regulated by various factors. ZEB1, which belongs to the human ZEB family transcription factors that bind to E-box promoter elements, is one of the most common prometastatic factors.
expression has frequently been observed at the migration front of a variety of epithelial tumors and reported as an activator in many cancers with metastatic capability.\textsuperscript{15,16} In particular, previous studies have shown that high ZEB1 expression in ESCC is closely correlated with advanced tumor stage and positive lymph node metastasis.\textsuperscript{17,18} However, the regulatory mechanism of ZEB1 expression in ESCC remains largely unknown.

In the present study, we found that Capn4 and ZEB1 expression were aberrantly upregulated in ESCC tissues and show a significantly positive correlation. Functional analysis showed that Capn4 facilitates ESCC invasion in vitro and metastasis in vivo by increasing ZEB1 expression. Further investigation indicated that Capn4 regulated ZEB1 expression by activating the Wnt/β-catenin signaling pathway. Thus, Capn4 may become a new therapeutic target or clinical biomarker for metastatic ESCC.

\textbf{Methods}

\textbf{Patients and samples}

Esophageal squamous cell carcinoma tumor tissues and corresponding normal esophageal epithelial tissues were obtained from 86 patients undergoing resection surgery at the Department of General Surgery, First Affiliated Hospital of Chinese PLA General Hospital from 2012 to 2017. All specimens from resection surgery were frozen and stored at \(-80°C\) until required. Informed consent was obtained from each patient, and the Ethics Committee of First Affiliated Hospital of Chinese PLA General Hospital approved the study protocol.

\textbf{Cell lines and culture conditions}

Human ESCC cell lines (ECA109, TE7, TE10, and EC9760) and human normal esophageal epithelial cells were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). All cells were cultured in Dulbecco’s modified essential medium supplemented with 10% fetal bovine serum (FBS; Hyclone, Logan, UT, USA), 100 U/mL penicillin, and 100 μg/mL streptomycin (Sigma-Aldrich, St Louis, MO, USA) and maintained in a humidified incubator at 37°C with 5% CO\(_2\).

\textbf{RNA extraction and quantitative real-time PCR assay}

Total RNA was isolated with Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. RNA was reverse transcribed using the PrimeScript RT Reagent Kit (Invitrogen, USA) and quantitative real-time PCR (qRT-PCR) was performed using SYBR Premix Ex Taq (TaKaRa, Dalian, China), following the manufacturer’s instructions. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal control. The primers used for qRT-PCR assay were as follows: Capn4 primers, forward: 5’-CAATGTCCGTTTCGCTCTA-3’; reverse: 5’-GGAGTTCTGGAATCTGTTTC-3’. ZEB1 primers, forward: 5’-AGCGAGGTAAGTTGCGTCT-3’; reverse: 5’-AGGTTTTCTGGCCATACCG-3’. GAPDH primers, forward: 5’-CTGGGCTACACTGAGCACC-3’, reverse: 5’-AAGTGTCGTGGAGGGCAATG-3’. The comparative 2\(^{-ΔΔCt}\) method was applied to develop qRT-PCR to analyze the Capn4 or ZEB1 expression pattern in ESCC. A value of \(ΔΔCt = −1\) was established as the cutoff line between high or low Capn4 or ZEB1 expression in qRT-PCR.

\textbf{Western blot assay}

Western blot analysis for specific protein expression was performed using standard methods. The antibodies used were as follows: anti-Capn4 (1:1000), anti-β-catenin (Abcam, Cambridge, MA, USA); anti-ZEB1 (1:1000, Cell Signaling Technology, Danvers, MA, USA); and anti-GAPDH (1:1000, Santa Cruz, Biotechnology Inc., Santa Cruz, CA, USA). The signals were detected by enhanced chemiluminescence (Pierce Biotechnology, Rockford, IL, USA).

\textbf{Constructs and plasmids}

The RNA duplexes for short hairpin RNA (shRNA)-mediated Capn4, ZEB1, and β-catenin silencing were synthesized by Genepharma (Shanghai, China). Capn4, ZEBQ, and β-catenin plasmids were purchased from Genepharma. Transfections of the shRNA and overexpression vector in ESCC cells were performed using Lipofectamine 2000 Transfection Reagent (Invitrogen, USA) following the manufacturer’s recommended protocol.

\textbf{Cell migration and invasion assay}

The migration ability of ESCC cells was tested in a Transwell Boyden Chamber (8 mm pore size; BD Biosciences, San Jose, CA, USA), as previously described.\textsuperscript{19} For the cell invasion assay, the polycarbonate membranes of the upper compartment of the chambers were precoated with a matrix gel.

\textbf{In vivo tumor metastatic assay}

Esophageal squamous cell carcinoma cells overexpressing or silencing Capn4 were transplanted into SCID beige mice via tail vein injection. The mice were sacrificed and dissected 12 weeks later to examine lung tissue. Lung metastatic nodules were counted for statistical analysis.
The Ethics Committee for Animal Experiments of the First Affiliated Hospital of Chinese PLA General Hospital approved the animal experiments, which were performed in accordance with the "Guide for the Care and Use of Laboratory Animals."

**Statistical analysis**

All data are expressed in terms of means ± standard error of the mean. Significant differences were analyzed using the Student’s t-test and two-tailed distribution. Spearman’s correlation analyses were used to identify the correlation between Capn4 and ZEB1. P < 0.05 was considered statistically significant.

**Results**

**Capn4 and ZEB1 expression are both upregulated in esophageal squamous cell carcinoma (ESCC) tissues and are closely related to progression**

To explore the expression and significance of Capn4 and ZEB1 in ESCC tissues, we initially examined their expression in 86 ESCC tissues and corresponding normal esophageal epithelial tissues. As shown in Figure 1a,b, the average fold change of Capn4 and ZEB1 messenger RNA (mRNA) expression in tumor tissues was significantly higher than that in paired normal tissues. The qRT-PCR results revealed that Capn4 was overexpressed in 65.1% (56/86) of ESCC specimens detected, and ZEB1 was upregulated in 61.6% (53/86) of ESCC tissues. Consistently, Western blot results showed that the Capn4 and ZEB1 protein levels were significantly elevated in the ESCC tissues (Fig 1c–e). Scatter plots showed that Capn4 and ZEB1 mRNA and protein expression levels were positively correlated in ESCC tissues (Fig 1f,g).

We then analyzed the correlation between high Capn4 and ZEB1 expression and ESCC clinicopathologic parameters. The results showed that both Capn4 and ZEB1 overexpression were closely correlated with advanced tumor stage, positive lymph node metastasis, and greater tumor depth (Table 1). These results suggested a positive correlation between Capn4 and ZEB1 expression in ESCC tumors, and positive or enhanced Capn4 expression was an indicator for metastasis.

**Silencing Capn4 reduces ZEB1 expression and suppresses ESCC invasion and metastasis**

To explore whether Capn4 regulated ZEB1 expression in ESCC cells, we initially examined the expression level of
Capn4 and ZEB1 in four human ESCC cell lines (ECA109, TE7, TE10, and EC9760) and human normal esophageal epithelial cells. The results indicated that Capn4 and ZEB1 expression in ESCC cells was higher than in normal esophageal epithelial cells (Fig 2a). We then stably transfected a Capn4-specific shRNA (shCapn4) into ECA109 and TE7 cells. qRT-PCR and Western blotting results showed that knockdown of Capn4 reduced ZEB1 mRNA and protein levels in the ECA109 and TE7 cells (Fig 2b–d). Furthermore, we examined the effects of Capn4 on ESCC cell metastasis by Transwell assay. As shown in Figure 2e–h, Capn4 knockdown significantly suppressed ESCC cell metastasis. Our results showed that the simultaneous silencing of Capn4 and ZEB1 dramatically suppressed ESCC cell migration and invasion (Fig S1). We further examined the effects of Capn4 on ESCC metastasis by in vivo tumor metastatic assay. As shown in Figure 2i, there were fewer lung metastatic nodules in the shCapn4 group than in the control group. Histological staining was performed to further confirm the presence of lung metastasis (Fig 2j). The results indicated that Capn4 silencing could reduce ZEB1 expression and thus inhibit ESCC invasion and metastasis.

Table 1 Correlation between Capn4 or ZEB1 and clinicopathologic characteristics in esophageal squamous cell carcinoma patients

| Pathologic characteristics | N | Low | High | P | Low | High | P |
|----------------------------|---|-----|------|---|-----|------|---|
| Age (years)                |   |     |      | NS|     |      | NS|
| < 50                       | 36| 12  | 24   |   | 14  | 22   |   |
| ≥ 50                       | 50| 18  | 32   |   | 19  | 31   |   |
| Gender                     |   |     |      | NS|     |      | NS|
| Female                     | 26| 8   | 18   |   | 10  | 16   |   |
| Male                       | 60| 22  | 38   |   | 23  | 37   |   |
| Histological grade         |   |     |      | P = 0.036|   | P = 0.031|   |
| G1                         | 22| 13  | 9    |   | 14  | 8    |   |
| G2                         | 46| 15  | 31   |   | 16  | 30   |   |
| G3                         | 18| 2   | 16   |   | 3   | 15   |   |
| Tumor location             |   |     |      | NS|     |      | NS|
| Upper                      | 19| 6   | 13   |   | 7   | 12   |   |
| Lower                      | 40| 15  | 25   |   | 16  | 24   |   |
| Tumor stage                |   |     |      | P = 0.009 |   | P = 0.0029 |   |
| I                          | 26| 17  | 9    |   | 18  | 8    |   |
| II                         | 30| 11  | 19   |   | 10  | 20   |   |
| III                        | 20| 2   | 18   |   | 4   | 16   |   |
| IV                         | 10| 0   | 10   |   | 1   | 9    |   |
| Tumor depth                |   |     |      | P = 0.001 |   | P = 0.001 |   |
| T1–2                       | 22| 14  | 8    |   | 16  | 6    |   |
| T3–4                       | 64| 16  | 48   |   | 17  | 47   |   |
| Lymph node metastasis      |   |     |      | P = 0.003 |   | P = 0.001 |   |
| Negative                   | 50| 24  | 26   |   | 27  | 23   |   |
| Positive                   | 36| 6   | 30   |   | 6   | 30   |   |

NS, no statistical significance.

ZEB1 is required for Capn4-mediated metastasis of ESCC cells

To further confirm that Capn4 mediates ESCC metastasis by regulating ZEB1, we increased the expression of ZEB1 in Capn4 silenced ESCC cells. Capn4 knockdown decreased ZEB1 expression, whereas ZEB1 upregulation attenuated the loss of ZEB1 expression in Capn4 silenced ECA109 cells. ZEB1 overexpression reversed the effects of decreased migration and invasion induced by Capn4 downregulation (Fig 3a–c). Additionally, the in vivo tumor metastatic assay showed that ZEB1 upregulation increased lung metastasis in ESCC cells, which had been inhibited by Capn4-knockdown (Fig. 3d). Conversely, ZEB1 downregulation inhibited ZEB1 expression and significantly reduced cell metastasis in Capn4-overexpressing ESCC cells (Fig 3e–h). Collectively, these results confirm that ZEB1 is crucial for Capn4-mediated ESCC metastasis.

Capn4 regulates ZEB1 expression through the Wnt/β-catenin signaling pathway in ESCC cells

Previous studies have reported that Capn4 promotes the invasion and metastasis of many cancers by activating the
Stable knockdown of Capn4 reduced ZEB1 expression and inhibited esophageal squamous cell carcinoma (ESCC) invasion and metastasis in vitro and in vivo. (a) Quantitative real-time PCR (qRT-PCR) analysis of Capn4 and ZEB1 expression in human esophageal epithelial and ESCC cell lines. (b,c) qRT-PCR analyses were used to detect Capn4 and ZEB1 messenger RNA (mRNA) expression in ECA109 and TE7 cells stably transfected with the short hairpin negative control (shNC) vector or shCapn4 plasmid (**P < 0.01). (d) Determination (left) and quantification (right) of Capn4 and ZEB1 protein levels in ECA109 and TE7 cells stably transfected with the shNC vector or the shCapn4 plasmid. Glyceraldehyde 3-phosphate dehydrogenase (GADPH) was used as a loading control (*P < 0.05). (e,g) Transwell migration assays of ECA109 and TE7 cells with stable Capn4 knockdown (*P < 0.05). (f,h) Transwell invasion assays of ECA109 and TE7 cells transfected with shCapn4 plasmid (*P < 0.05). (i) Statistical analysis of lung metastatic nodules. (n = 6/group; **P < 0.01). (j) Hematoxylin and eosin staining of the paraffin embedded sections of lung metastatic nodules.
Wnt/β-catenin signaling pathway. Many studies have also shown that ZEB1 is a downstream target of the Wnt/β-catenin signaling pathway. Thus, we speculated that Capn4 regulates ZEB1 expression by activating the Wnt/β-catenin signaling pathway in ESCC cells.

To test this hypothesis, we first observed whether Capn4 regulated the Wnt/β-catenin signaling pathway in ESCC cells. The results showed that as Capn4 expression decreased, total and nuclear β-catenin expression reduced in ECA109 cells (Fig 4a). Meanwhile, in a TOP-Flash reporter luciferase assay, silencing of Capn4 in ECA109 cells decreased the transcriptional activity of TCF4 compared to the control groups (Fig 4b). In addition, we found that upregulation of β-catenin reversed the effects of decreased ZEB1 expression and cell migration and invasion induced by Capn4 knockdown (Fig. 4c–e). In contrast, upregulation of Capn4 significantly increased total and nuclear β-catenin expression levels, and the transcriptional activity of TCF4 was also increased (Fig 4f,g). Knockdown of β-catenin significantly suppressed the increase in ZEB1 expression and reduced cell metastasis in Capn4-overexpressing ESCC cells (Fig 4h–i). Overall, these data showed that Capn4 promotes ESCC metastasis via the Wnt/β-catenin/ZEB1 axis.

Discussion

Esophageal squamous cell carcinoma is one of the most common malignancies, with low five-year overall survival. Because metastasis causes 90% of all cancer-related deaths, including ESCC, a deep understanding of the mechanisms of metastasis is required. Capn4 is a potent oncogene and plays a crucial role in the metastasis of several tumors. However, no information is currently available on the specific role or molecular mechanism of Capn4 in ESCC. Herein, we prove that both Capn4 and ZEB1 overexpression are closely associated with the invasive pathologic features of ESCC. We also found that Capn4 silencing could reduce ZEB1 expression and decrease ESCC invasion and metastasis in vitro and in vivo. Furthermore, our results show that Capn4 positively regulates ZEB1 expression by activating the Wnt/β-catenin signaling pathway in ESCC. Our results indicate that Capn4 plays a critical role in ESCC metastasis, and could be a potential therapeutic target.

Metastasis is an essential biological characteristic of many cancers and is associated with cancer progression. ZEB1 is important factor in the metastatic process, which drives epithelial-to-mesenchymal transition. Increasing evidence indicates that ZEB1 is deeply involved...
in cancer invasion and metastasis.\textsuperscript{15,16} Thus, elucidation of ZEB1 expression mechanisms will improve understanding of the process of ESCC metastasis. Our data confirm that downregulation of Capn4 expression decreases ZEB1 expression and inhibits ESCC metastasis. Furthermore, ZEB1 overexpression reverses the effects of decreased cell invasion and migration induced by Capn4 knockdown, whereas ZEB1 silencing significantly decreases Capn4-enhanced cell proliferation. These results show that Capn4 positively regulates ZEB1 expression and thus influences ESCC metastasis, suggesting a new regulatory mechanism of ZEB1.

Capn4 is reported to contribute to the invasion and metastasis of many cancers by activating the Wnt/\(\beta\)-catenin pathway. Our study provides evidence that Capn4 enhances ZEB1 expression through this pathway, and our results support a new regulatory mechanism of ZEB1.
signaling pathway. Additionally, β-catenin and TCF4 can bind the promoter region of ZEB1 to promote its expression.29,30 Therefore, we predicted that Capn4 regulates the Wnt signaling pathway target gene ZEB1 to promote ESCC metastasis. First, we validated that Capn4 could activate the Wnt/β-catenin signaling pathway in ESCC cells. Second, Capn4 knockdown led to the recovery of ZEB1 protein levels in cells overexpressing β-catenin. Third, Capn4 upregulation decreased ZEB1 in cells silencing β-catenin. Therefore, Capn4 increases Wnt/β-catenin signaling pathway activity, which induces increased ZEB1 expression in ESCC cells.

In summary, our results provide the first evidence that Capn4 functions as an oncogene in ESCC. Moreover, we not only clarify the function of Capn4 in ESCC metastasis, but also provide novel insight into the mechanism of Capn4, which modulates the Wnt/β-catenin/ZEB1 axis. These results highlight the significant power of Capn4 expression, which could serve as a therapeutic target in ESCC in the future.

Disclosure

No authors report any conflict of interest.

References

1 Rustgi AK, El-Serag HB. Esophageal carcinoma. N Engl J Med 2014; 371: 2499–509.
2 Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87–108.
3 Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11–30.
4 Vallbohmer D, Brabender J, Metzger R, Holscher AH. Genetics in the pathogenesis of esophageal cancer: Possible predictive and prognostic factors. J Gastrointest Surg 2010; 14 (Suppl 1): S75–80.
5 Saez ME, Ramirez-Lorca R, Moron FJ, Ruiz A. The therapeutic potential of the calpain family: New aspects. Drug Discov Today 2006; 11: 917–23.
6 Arthur JS, Elce JS, Hegadorn C, Williams K, Greer PA. Disruption of the murine calpain small subunit gene, Capn4: Calpain is essential for embryonic development but not for cell growth and division. Mol Cell Bioi 2000; 20: 4474–81.
7 Yang MF, Lou YL, Liu SS et al. Capn4 overexpression indicates poor prognosis of ovarian cancer patients. J Cancer 2018; 9: 304–9.
8 Li Y, Zhang Z, Zhou X et al. The oncoprotein HBXIP enhances migration of breast cancer cells through increasing filopodia formation involving MEK2/ERK1/2/Capn4 signaling. Cancer Lett 2014; 355: 288–96.
9 Cheng F, Mohammed MM, Li Z et al. Capn4 promotes colorectal cancer cell proliferation by increasing MAPK7 through activation of the Wnt/beta-catenin pathway. Exp Cell Res 2018; 363: 235–42.
10 Shi B, Wang Y, Yin F. MALAT1/miR-124/Capn4 axis regulates proliferation, invasion and EMT in nasopharyngeal carcinoma cells. Cancer Biol Ther 2017; 18: 792–800.
11 Zheng PC, Chen X, Zhu HW et al. Capn4 is a marker of poor clinical outcomes and promotes nasopharyngeal carcinoma metastasis via nuclear factor-kappaB-induced matrix metalloproteinase 2 expression. Cancer Sci 2014; 105: 630–8.
12 Dai Z, Zhou SL, Zhou ZJ et al. Capn4 contributes to tumour growth and metastasis of hepatocellular carcinoma by activation of the FAK-Src signalling pathways. J Pathol 2014; 234: 316–28.
13 Tsai JH, Yang J. Epithelial–mesenchymal plasticity in carcinoma metastasis. Genes Dev 2013; 27: 2192–206.
14 Hill L, Browne G, Tulchinsky E. ZEB/miR-200 feedback loop: At the crossroads of signal transduction in cancer. Int J Cancer 2013; 132: 745–54.
15 Caramel J, Ligier M, Puisieux A. Pleiotropic roles for ZEB1 in cancer. Cancer Res 2018; 78: 30–5.
16 Wang Y, Wen M, Kwon Y et al. CUL4A induces epithelial–mesenchymal transition and promotes cancer metastasis by regulating ZEB1 expression. Cancer Res 2014; 74: 520–31.
17 Yang X, Wang Q, Dai W, Zhang J, Chen X. Overexpression of zinc finger E-box binding homeobox factor 1 promotes tumor invasiveness and confers unfavorable prognosis in esophageal squamous cell carcinoma. Tumour Biol 2014; 35: 11977–84.
18 Yokobori T, Suzuki S, Tanaka N et al. miR-150 is associated with poor prognosis in esophageal squamous cell carcinoma via targeting the EMT inducer ZEB1. Cancer Sci 2013; 104: 48–54.
19 Zhang S, Hong Z, Chai Y et al. CSN5 promotes renal cell carcinoma metastasis and EMT by inhibiting ZEB1 degradation. Biochem Biophys Res Commun 2017; 488: 101–8.
20 Yang X, Sun J, Xia D et al. Capn4 enhances osteopontin expression through activation of the Wnt/beta-catenin pathway to promote epithelial ovarian carcinoma metastasis. Cell Physiol Biochem 2017; 42: 185–97.
21 Wang E, Wang D, Li B et al. Capn4 promotes epithelial–mesenchymal transition in human melanoma cells through activation of the Wnt/beta-catenin pathway. Oncol Rep 2017; 37: 379–87.
22 Hu H, Wang G, Li C. miR-124 suppresses proliferation and invasion of nasopharyngeal carcinoma cells through the Wnt/beta-catenin signaling pathway by targeting Capn4. Onco Targets Ther 2017; 10: 2711–20.
23 Zhang M, Miao F, Huang R et al. RHBDD1 promotes colorectal cancer metastasis through the Wnt signaling pathway and its downstream target ZEB1. J Exp Clin Cancer Res 2018; 37: 22.
24 Kahlerdt UD, Maciacyzk D, Doostkam S et al. Activation of canonical WNT/beta-catenin signaling enhances in vitro...
motility of glioblastoma cells by activation of ZEB1 and other activators of epithelial-to-mesenchymal transition. Cancer Lett 2012; 325: 42–53.

25 Gupta GP, Massague J. Cancer metastasis: Building a framework. Cell 2006; 127: 679–95.

26 Kalluri R, Weinberg RA. The basics of epithelial–mesenchymal transition. J Clin Invest 2009; 119: 1420–8.

27 Xia L, Huang W, Tian D et al. Forkhead box Q1 promotes hepatocellular carcinoma metastasis by transactivating ZEB2 and VersicanV1 expression. Hepatology 2014; 59: 958–73.

28 Goossens S, Vandamme N, Van Vlierberghe P, Berx G. EMT transcription factors in cancer development re-evaluated: Beyond EMT and MET. Biochim Biophys Acta 2017; 1868: 584–91.

29 Sanchez-Tillo E, de Barrios O, Siles L, Cuatrecasas M, Castells A, Postigo A. Beta-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness. Proc Natl Acad Sci U S A 2011; 108: 19204–9.

30 He YM, Xiao YS, Wei L, Zhang JQ, Peng CH. CUL4B promotes metastasis and proliferation in pancreatic cancer cells by inducing epithelial–mesenchymal transition via the Wnt/beta-catenin signaling pathway. J Cell Biochem 2018; 119: 5308–23.

**Supporting Information**

Additional Supporting Information may be found in the online version of this article at the publisher’s website:

Figure S1. Simultaneous silencing Capn4 and ZEB1 significantly inhibited the migration and invasion abilities of esophageal squamous cell carcinoma (ESCC) cells. (a,c) Determination and (b,d) quantification of Capn4 and ZEB1 protein levels in ECA109 and TE7 cells stably transfected with the shNC vector, shCapn4 or the shCapn4 + shZEB1 plasmid. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a loading control (*P < 0.05). (e,f) Transwell migration assays of ECA109 and TE7 cells following simultaneous knockdown of Capn4 and ZEB1 (*P < 0.05).